INK cells after chemoradiation for small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have small cell lung cancer that is locally advanced or has spread, and cannot be removed by surgery.
- You must be in generally good health (able to do daily activities without help).
- You must have a life expectancy of at least 3 months.
- You must not have serious heart, kidney, liver, or lung problems.
- You must not have active hepatitis, HIV, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
This trial tests an experimental immune cell therapy called iNK for people with advanced solid tumors that no longer respond to standard treatments. The therapy uses natural killer (NK) cells, which are part of your immune system, to target and attack cancer cells. The goal is to see if it is safe and if it can help shrink tumors or slow their growth.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.